Oligopeptides for Cancer Immunotherapy
Cytotoxic T lymphocytes (CTL) kill tumour cells upon recognition of oligopeptides derived from tumour-associated antigens (TAA). These are presented by major histocompatibility complex (MHC) class I molecules on the surface of the tumour cells. TAA of certain categories differ with respect to their tumour specificity: mutated antigens and so-called “cancer/germ line” (C/G) antigens are considered strictly or highly tumour specific whereas differentiation antigens are expressed in tumours and the tissues the tumours originate from. The expression of C/G antigens was demonstrated in a variety of cancer types.
Further Information: PDF
IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-50
Contact
Dr. Klaus Kobek
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Lighting up the future
New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…
Researchers crack sugarcane’s complex genetic code
Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….
Evolution of the most powerful ocean current on Earth
The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….